HCPCS Level II code Q5118 denotes a 10 mg unit of bevacizumab-bvzr (Zirabev), a biosimilar to bevacizumab used as an intravenous oncologic biologic. Nationally, biosimilar billing codes like Q5118 matter for cost management, formulary placement, and claims processing because they enable specific identification of biosimilar agents versus reference biologics. Payors use these codes to track utilization, apply coverage policies, and manage reimbursement for high-cost injectable therapies.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what Q5118 represents clinically and operationally, typical sites of service where the product is administered, and the practical implications for payers and billing workflows. The publication covers benchmarks for unitization and billing practices, relevant policy and coding updates affecting biosimilars, and clinical context for use of bevacizumab biosimilars in oncology infusion settings. Information not supplied in the input — such as associated taxonomies, specific ICD-10 diagnoses, and payer-specific coverage rules — is identified as unavailable to maintain accuracy.